Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt after a series of trial results have left investors feeling unsatisfied.
Related Posts
Trump orders all federal diversity, equity and inclusion employees placed on paid leave starting Wednesday
The Trump administration also directed government agencies to draw up plans for firing workers in DEI roles.
Jeremy Siegel is cautious on the Mag 7: ‘We have these two markets’
The Wharton School professor is uncertain whether the megacaps can continue to enjoy the run they’ve had, and expects other parts of the market can […]
Asia-Pacific markets track Wall Street gains on strong key economic data, corporate earnings
Asia-Pacific markets were set to open higher, tracking Wall Street gains after the U.S. S&P 500 climbed to a fresh record.